[Skip to Navigation]
Original Investigation
May 4, 2021

α2-Adrenergic Agonists or Stimulants for Preschool-Age Children With Attention-Deficit/Hyperactivity Disorder

Author Affiliations
  • 1Division of Developmental Medicine, Boston Children’s Hospital, Boston, Massachusetts
  • 2Children's Hospital of Philadelphia, Philadelphia, Pennsylvania
  • 3Perelman School of Medicine at University of Pennsylvania
  • 4University of Oklahoma Health Sciences Center, Oklahoma City
  • 5Department of Pediatrics, Keck School of Medicine, University of Southern California, Los Angeles
  • 6Division of General Pediatrics, Children's Hospital Los Angeles, Los Angeles, California
  • 7University of Colorado School of Medicine, Children's Hospital Colorado, Aurora
  • 8Medical University of South Carolina, Charleston
  • 9Stanford University, Stanford, California
  • 10Atrium Health, Concord, North Carolina
  • 11Division of Developmental and Behavioral Pediatrics, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania
JAMA. 2021;325(20):2067-2075. doi:10.1001/jama.2021.6118
Key Points

Question  For preschool-age children with attention-deficit/hyperactivity disorder initiating α2-adrenergic agonist or stimulant medications in developmental-behavioral pediatric practices, what improvements and adverse effects were noted?

Findings  In this retrospective review of health records of 497 children, improvement was noted in 115 of 175 children (66%) who received α2-adrenergic agonists and 251 of 322 children (78%) who received stimulants, with differences in adverse effect profiles noted between medication classes.

Meaning  Further research from randomized clinical trials is needed to assess comparative effectiveness of α2-adrenergic agonists vs stimulants for preschool-age children with ADHD.

Abstract

Importance  Attention-deficit/hyperactivity disorder (ADHD) is diagnosed in approximately 2.4% of preschool-age children. Stimulants are recommended as first-line medication treatment. However, up to 25% of preschool-age children with ADHD are treated with α2-adrenergic agonist medications, despite minimal evidence about their efficacy or adverse effects in this age range.

Objective  To determine the frequency of reported improvement in ADHD symptoms and adverse effects associated with α2-adrenergic agonists and stimulant medication for initial ADHD medication treatment in preschool-age children.

Design, Setting, and Participants  Retrospective electronic health record review. Data were obtained from health records of children seen at 7 outpatient developmental-behavioral pediatric practices in the Developmental Behavioral Pediatrics Research Network in the US. Data were abstracted for 497 consecutive children who were younger than 72 months when treatment with an α2-adrenergic agonist or stimulant medication was initiated by a developmental-behavioral pediatrician for ADHD and were treated between January 1, 2013, and July 1, 2017. Follow-up was complete on February 27, 2019.

Exposures  α2-Adrenergic agonist vs stimulant medication as initial ADHD medication treatment.

Main Outcomes and Measures  Reported improvement in ADHD symptoms and adverse effects.

Results  Data were abstracted from electronic health records of 497 preschool-age children with ADHD receiving α2-adrenergic agonists or stimulants. Median child age was 62 months at ADHD medication initiation, and 409 children (82%) were males. For initial ADHD medication treatment, α2-adrenergic agonists were prescribed to 175 children (35%; median length of α2-adrenergic agonist use, 136 days) and stimulants were prescribed to 322 children (65%; median length of stimulant use, 133 days). Improvement was reported in 66% (95% CI, 57.5%-73.9%) of children who initiated α2-adrenergic agonists and 78% (95% CI, 72.4%-83.4%) of children who initiated stimulants. Only daytime sleepiness was more common for those receiving α2-adrenergic agonists vs stimulants (38% vs 3%); several adverse effects were reported more commonly for those receiving stimulants vs α2-adrenergic agonists, including moodiness/irritability (50% vs 29%), appetite suppression (38% vs 7%), and difficulty sleeping (21% vs 11%).

Conclusions and Relevance  In this retrospective review of health records of preschool-age children with ADHD treated in developmental-behavioral pediatric practices, improvement was noted in the majority of children who received α2-adrenergic agonists or stimulants, with differing adverse effect profiles between medication classes. Further research, including from randomized clinical trials, is needed to assess comparative effectiveness of α2-adrenergic agonists vs stimulants.

Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words
    ×